How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool. by Ettori-Ajasse, I et al.
RESEARCH Open Access
How pragmatic are the randomised trials
used in recommendations for control of
glycosylated haemoglobin levels in type 2
diabetic patients in general practice: an
application of the PRECIS II tool
Isabelle Ettori-Ajasse1* , Elise Tatin2, Gordon Forbes3, Sandra Eldridge4 and Clarisse Dibao-Dina1,5
Abstract
Background: Recommendations for good clinical practice have been reported to be difficult to apply in real life by
primary care clinicians. This could be because the clinical trials at the origin of the guidelines are based on explanatory
trials, conducted under ideal conditions not reflecting the reality of primary care, rather than pragmatic trials
conducted under real-life conditions. The objective of this study was to evaluate how pragmatic are the clinical trials
used to build the French High Authority of Health’s recommendations on the management of type II diabetes.
Methods: Trials from the 2013 Cochrane meta-analysis that led to the 2013 French High Authority of Health’s
recommendations on the management of type II diabetes were selected. Each trial was analysed by applying the
PRECIS-2 tool to evaluate whether the trial was pragmatic or explanatory, according to the nine domains of PRECIS-2.
Each domain was scored between 1 (very explanatory) and 5 (very pragmatic) by two blinded researchers, and
consensus was reached with a third researcher in case of discrepancy. Median scores were calculated for each of the
nine domains.
Results: Twenty-three articles were analysed. Eight out of nine domains – namely eligibility, recruitment, setting,
organisation, flexibility of delivery, flexibility of adherence, follow-up, and primary outcome – had a median score of
less than 3, indicating a more explanatory design. Only the primary analysis domain had a score indicating a more
pragmatic approach (median score of 4). In more than 25% of the articles, data to score the domains of recruitment,
flexibility of delivery, flexibility of adherence, and primary analysis were missing.
Conclusions: Trials used to build French recommendations for good clinical practice for the management of type 2
diabetes in primary care were more explanatory than pragmatic. Policy-makers should encourage the funding of
pragmatic trials to evaluate the different strategies proposed for managing the patient’s treatment according to HbA1C
levels and give clinicians feasible recommendations.
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Introduction
In France, recommendations to improve the management
of patients with type II diabetes are based on the glycosyl-
ated haemoglobin (HbA1C) levels [1]. Practitioners have
to adapt the patient’s treatment for them to achieve the
recommended HbA1C levels according to their condition
[1]. For most patients with type 2 diabetes, an HbA1c tar-
get less than or equal to 7% is recommended. For elderly
or frail patients, the HbA1C target may be 8% or even 9%
[1]. For newly diagnosed young and healthy patients, the
HbA1C target is 6.5% [1].
These recommendations for managing the patient’s
treatment according to HbA1C levels are based mainly
on experts’ views of existing evidence. This evidence is
often based on randomised trials. The latest guidelines
are based on a 2013 Cochrane review that considered
the effects of targeted intensive glycaemic control com-
pared with conventional glycaemic control in patients
with type 2 diabetes [2]. The review included rando-
mised trials comparing mortality, macrovascular and
microvascular complications and adverse events depend-
ing on predefined HbA1c targets [2]. However, there is a
lack of studies comparing the different strategies, based on
morbidity and mortality outcomes. Of the 45 recommen-
dations, none is grade A (i.e., high quality of evidence,
usually from well-performed randomised controlled trials),
four are grade B (i.e., moderate quality of evidence, usually
from randomised controlled trials with important limita-
tions or very strong evidence from other designs) and 41
are grade C (i.e., low quality of evidence, usually from ob-
servational studies, clinical experience or controlled trials
with serious flaws) [1].
However, an intensive strategy of management of
HbA1C levels is not without risk: over a treatment period
of five years, 117 to 150 patients would need to be treated
to avoid one myocardial infarction and 32 to 142 patients
to avoid one episode of microalbuminuria, whereas one
severe episode of hypoglycaemia would occur for every 15
to 52 patients [3]. Severe hypoglycaemia was defined as a
blood glucose level of less than 2.8mmol/L (50mg/dL) in
patients with transient dysfunction of the central nervous
system who were unable to treat themselves (requiring
help from another person) [4].
For different reasons, practitioners do not follow rec-
ommendations [5]: lack of trust in the scientific basis of
the recommendations, difficulties in applying the recom-
mendations in real life, or for other reasons particular to
the practitioner and their professional environment. The
lack of trust in the scientific basis of the recommenda-
tions may come from the fact that the trials the recom-
mendations are based on are not pragmatic, leading to
results that cannot be applied in usual care.
A pragmatic trial is designed for testing the effective-
ness of an intervention under real-world conditions,
whereas an explanatory trial is designed for testing an
intervention under ideal experimental conditions [6]. As
mentioned by Godwin et al., “The explanatory trial seeks to
maximise the internal validity by assuring rigorous control
of all variables other than the intervention. The pragmatic
trial seeks to maximise external validity to ensure that the
results can be generalized” [7]. Trials are rarely wholly prag-
matic or explanatory, and different elements of a trial may
be more pragmatic or more explanatory. An assessment of
how pragmatic or explanatory a trial is can be made by
using PRECIS-2, a tool designed to evaluate whether a trial
is more explanatory or pragmatic across nine different
domains: eligibility criteria, recruitment, setting, organisa-
tion, flexibility (delivery), flexibility (adherence), follow-up,
primary outcome, and primary analysis [8].
Therefore, we decided to determine whether the trials
at the basis of the recommendations for the manage-
ment of type II diabetes were more pragmatic or
explanatory by using the PRECIS-2 tool. We decided to
apply it to trials that were selected to build the recom-
mendations on the management of type II diabetes on
the basis of HbA1C levels [1]. Our aim was to determine
whether those trials were more explanatory or pragmatic
according to the PRECIS-2 tool.
Methods
Selection of randomised trials
Studies were eligible if they were randomised trials and in-
cluded in the most recent Cochrane meta-analysis con-
ducted on the topic that was cited in the recommendations
and published in 2013 [2]. We restricted eligibility to the
most recent Cochrane meta-analysis as recommendations
were based on the results of the trials included in this
review. Articles that reported studies that were not rando-
mised trials or meta-analyses of randomised trials, articles
reporting ancillary studies (i.e., studies derived from an ori-
ginal study), and articles written in a language other than
English or French were excluded.
Data collection
Each selected trial was analysed by using the PRECIS-2 tool
[8]. Scores for each of the nine domains were from 1 (very
explanatory) to 5 (very pragmatic) using a 5-point Likert
scale [8]. A score of 3 was defined as equally pragmatic and
explanatory [8]. In order to harmonise the scoring of the
PRECIS-2 tool, the tool was tested on three randomly se-
lected trials by the two researchers who would analyse all of
the trials (ET and CD-D) and discussions on the scoring of
the domains were carried out with all of the researchers
(ET, CD-D, IE-A, SE, and GF) before the analysis of the
remaining trials. The nine domains of the PRECIS-2 tool
are described in Additional file 1: Appendix 1, and the
result of the discussions on the scoring is detailed in
Additional file 1: Appendix 2. Data were collected by two
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researchers (ET and CD-D) blinded from each other
and using a standardised form developed by the re-
searchers (CD-D, IE-A, SE, and GF). Collected data
included the characteristics of the trials (details of the
publication, design and main result) and scoring for
the nine domains of the PRECIS-2 tool. In case of in-
sufficient information in the selected article, the
protocol of the article was consulted if it was refer-
enced and published. After having collected the data,
the two researchers (ET and CD-D) shared the results
and discussed disagreeing scores to reach a consen-
sus. If consensus between ET and CD-D could not be
reached, the opinion of a third researcher (IE-A, SE
or GF) was used to establish a consensus.
Data analysis
The characteristics of the trials were analysed descrip-
tively. The median score and interquartile range (Q1;
Q3) over all trials were calculated for each domain in
the PRECIS-2 tool. We also performed a descriptive
analysis of the articles for which scoring needed a
consensus between researchers and where there were
missing data in the articles to score the domains of
the PRECIS-2 tool.
Results
Selection of articles
From the Cochrane meta-analysis published in 2013 on
the HbA1C target-based therapeutic strategy of type 2
diabetes, 28 randomised clinical trials were identified [2].
Of these 28 randomised trials, 23 trials were included in
the analysis (see Fig. 1).
Characteristics of the included trials
The characteristics of the included trials are shown in
Table 1. 2009 was chosen as a threshold date because
it corresponds to the date of the first publication of
the PRECIS tool [9]. All of the trials evaluated an
intervention involving delivering a drug to achieve
strict targets of HbA1C. The control group was a
group with a usual care strategy or with less stringent
blood glucose targets than the intervention group.
The details of the intervention and primary criteria
for each of the 23 trials are given in Additional file 1:
Appendix 3. Of the 23 studies analysed, 17 were con-
ducted in hospital settings.
Scoring of trials according to the PRECIS-2 tool
The median scores for each domain in the PRECIS-2
tool are shown in Table 2.
Eight out of nine PRECIS-2 domains had a median
score of less than 3. “Recruitment”, “Flexibility of adher-
ence” and “Primary outcome” were the hardest domains
for reaching the consensus between explanatory and
pragmatic.
The results were graphically represented with the
“wheel” of PRECIS-2 in Fig. 2.
The details of the median scores before and after con-
sensus are available in Additional file 1: Appendix 4.
For every PRECIS-2 domain, between 60% and 85%
of the articles required a consensus, mainly on the
degree to which the trial was pragmatic (between the
scores 4 or 5) or explanatory (between scores 1 or 2).
Disagreements between pragmatic score (>3) and ex-
planatory scores (<3) occurred in between 0% and
22% of articles, depending on which domain was
considered.
Fig. 1 Flowchart of the selected trials
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Discussion
Summary of results
We found that clinical trials contributing to recommen-
dations on the therapeutic strategy of type 2 diabetes
were more explanatory than pragmatic. In fact, only the
domain on primary analysis was more pragmatic with a
median score greater than 3 (4). The lack of information
reported in the article to score its explanatory or prag-
matic aspect concerned mainly recruitment, flexibility of
delivery, flexibility of adherence and primary analysis,
and more than 25% of articles had insufficient informa-
tion. The majority of the scoring has required a consen-
sus to define the degree to which the trial was pragmatic
or explanatory.
Interpretation of results
For eligibility, the selection of the population was more
explanatory than pragmatic. Most trials evaluated the
intervention under optimal conditions and not with pop-
ulations that would present in primary care. For ex-
ample, patients with comorbidities that could interfere
with study outcomes, patients living too far from the
study site, or patients who were unable to manage insu-
lin and cope with hypoglycaemia were excluded [10–13].
These highly selective samples excluded patients usually
encountered in general practice, which may be one of
the barriers to implementing recommendations in usual
care. Furthermore, some studies included very specific
populations, such as veterans, that were not comparable
with the typical French diabetic population [14].
Most of the trials were carried out in hospital settings,
leading to the scores for domains of setting, recruitment,
organisation, primary outcome and flexibility of delivery
being more explanatory than pragmatic. If recommenda-
tions of good clinical practice were addressed to the
management of hospitalised patients with diabetes, those
Table 1 Characteristics of the 23 included trials
Characteristics Number of
articles
Missing data
N (%) N (%)
Publication date Before 2009 14 (61) 0
After 2009 9 (39)
Countrya China 2 (9) 1 (4)
US 5 (22)
UK 4 (17)
Denmark 3 (13)
Netherlands 2 (9)
Canada 2 (9)
Japan 1 (4)
New Zealand 1 (4)
Swiss 2 (9)
Finland/Norway 1 (4)
Greece 2 (9)
Design Two parallel
groups
19 (83) 0
Three parallel
groups
3 (13)
Double factorial
design 2 × 2
1 (4)
Sample size median (Q1; Q3) 179 (82; 1068) 0
Number of centres Monocentric
studies
10 (45) 4 (17)
Pluricentric studies 12 (55)
Number of centres,
median (Q1; Q3)
14 (1; 40)
Follow-up in months,
median (Q1; Q3)
51 (6; 67) 1 (4)
aThe total number of countries cited exceeded the total number of trials as
some trials were conducted in several countries
Table 2 Median scores of the 23 trials for each domain of the PRECIS-2 tool
Title of domain Median score Number of articles
with missing data
Articles for which scoring
required a consensus
Articles for which scoring
required a consensus between
a score rather explanatory (<3)
or pragmatic (>3)
(Q1; Q3) N (%) N (%a) N (%a)
Eligibility 2 (1; 2)) 1/23 (4) 14/22 (64) 1/22 (5)
Recruitment 1 (1; 3) 10/23 (43) 10/13 (77) 5/13 (38)
Setting 2 (1; 2) 3/23 (13) 17/20 (85) 4/20 (20)
Organisation 2 (1; 2) 3/23 (13) 16/20 (80) 1/20 (5)
Flexibility of delivery 2 (2; 4) 6/23 (26) 13/17 (76) 1/17 (6)
Flexibility of adherence 2 (1.75; 2) 9/23 (39) 10/14 (71) 3/14 (21)
Follow up 2 (2; 3) 4/23 (17) 16/19 (84) 1/19 (5)
Primary outcome 2 (1; 3.25) 3/23 (13) 12/20 (60) 5/20 (25)
Primary analysis 4 (1; 5) 6/23 (26) 12/17 (71) 0/17 (0)
aThe consensus was any discrepancy in the scores between the two researchers (ET and CD-D)
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results would have been more pragmatic in that context.
However, some characteristics of the organisation or inter-
vention that are provided in the hospital setting would not
be available in primary care, such as involvement of specia-
lised staff to administer the treatment and educate the pa-
tient or more intensive monitoring of the patient [15–21].
In the hospital, the treatments were administered by nurses,
which ensured regular intake and reduced the risk of non-
compliance. On the other hand, the outpatient was autono-
mous, and there was no guarantee of compliance with the
treatment prescribed by the general practitioner. For the
primary outcome, the median score of 2 in favour of a ra-
ther explanatory methodological choice was because either
the primary outcome was not observable in general practice
or it required the intervention of specialists [20, 22, 23]. For
instance, the study by Natarajan et al. used the change of
volume of intimal hyperplasia within the stent as primary
outcome [22].
The domain on the primary analysis was the only one
out of the nine with a median score greater than 3, sug-
gesting that the majority of trials were more pragmatic in
relation to this domain. This was because most of the
studies analysed the results following the intention-to-
treat principle [24]. This sort of analysis is recommended
for intervention’s regulatory approval and in CONSORT
(Consolidated Standards of Reporting Trials) guidelines.
Strengths and limitations
Our study was the first from the perspective of the
French primary care setting to use a graphic tool to
illustrate that the trials on which recommendations for
good clinical practice were based were not pragmatic.
We chose to use the PRECIS-2 tool because it had
already been used successfully for a systematic review in
order to assess whether the pragmatism of the trials was
a source of heterogeneity in the trial results [25]. As a
prevention for a desirability bias according to our initial
hypothesis of an excess of explanatory trials, the re-
searchers had different backgrounds: an experienced
general practitioner (CD-D) and a medical student (ET)
independently scored the trials, whereas consensus was
reached thanks to a third general practitioner (IE-A) and
two biostatisticians (SE and GF) who studied the applic-
ability of the PRECIS-2 tool [26]. However, in our study,
many scores were finalised only after discussion between
researchers. Some areas of the PRECIS-2 tool were
subject to interpretation despite the examples given in
the article by Loudon et al. [8]. This can be explained
by the purpose for which the PRECIS-2 tool was cre-
ated, namely the evaluation of protocols intended for
researchers and not the evaluation of the published
trials. To be applicable for the latter objective would
require a greater precision in the way of scoring each
domain, to ensure a better homogeneity of the evalu-
ations of the trials.
There was also a lot of missing data in the articles
to score certain domains of PRECIS-2. However,
missing data were less frequent for domains that were
detailed in the CONSORT guidelines for reporting
randomised trials [24].
Fig. 2 Graphical representation of the PRECIS-2 wheel
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Implications
According to our results, the clinical trials on which rec-
ommendations for good clinical practice were based had
primarily explanatory features, which could constitute
an obstacle to the application of recommendations to
the therapeutic strategy of type 2 diabetes in general
practice. However, we cannot be sure that the lack of
pragmatism of the evidence of the guidelines is the only
reason why general practitioners do not follow the
guidelines. This can contribute to this lack of trust, but
other controversies around the evidence might also play
a role: in particular, the Cochrane review concluded that
there was no benefit of the intensive glycaemic control
on mortality compared with the conventional glycaemic
control, and French guidelines still recommended an
HbA1C targets less than 7% in most of the cases.
Ideally, both types of trials would be required: explana-
tory trials to demonstrate the efficacy of interventions
under ideal conditions and pragmatic trials performed
under the usual conditions of practice to improve the
applicability of the results in general practice. This re-
quires the involvement of general practitioners and their
patients in clinical research and also methodological and
organisational adaptations to integrate research into
daily care practice.
Conclusions
Our study has highlighted the fact that the clinical trials
leading to recommendations on the therapeutic strategy
of type 2 diabetes were more explanatory than prag-
matic. Diabetes researchers could concentrate on more
pragmatic trials. Policy-makers should encourage the
funding of pragmatic trials to evaluate the different strat-
egies proposed in the recommendations for managing
the patient’s treatment according to HbA1C levels.
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